Showing results (121-130 of 214) with videos related to

Sort By:
Pageof 22
AIDS (London, England)|March 28, 2014
Simplification to rilpivirine/emtricitabine/tenofovir disoproxil fumarate from ritonavir-boosted protease inhibitor antiretroviral therapy in a randomized trial of HIV-1 RNA-suppressed participantsFrank J Palella, Martin Fisher, Pablo Tebas, et al.
Science Immunology|June 17, 2017
Successive annual influenza vaccination induces a recurrent oligoclonotypic memory response in circulating T follicular helper cellsRamin Sedaghat Herati, Alexander Muselman, Laura Vella, et al.
AIDS Research and Human Retroviruses|December 16, 2020
Safety, Immune, and Antiviral Effects of Pegylated Interferon Alpha 2b Administration in Antiretroviral Therapy-Suppressed Individuals: Results of Pilot Clinical TrialEmmanouil Papasavvas, Livio Azzoni, Amélie Pagliuzza, et al.
Open Forum Infectious Diseases|May 9, 2017
A Randomized Placebo Controlled Trial of Aspirin Effects on Immune Activation in Chronically Human Immunodeficiency Virus-Infected Adults on Virologically Suppressive Antiretroviral TherapyMeagan P O'Brien, Peter W Hunt, Douglas W Kitch, et al.
Journal of Virology|September 19, 2008
Human immunodeficiency virus type 1 Nef induces programmed death 1 expression through a p38 mitogen-activated protein kinase-dependent mechanismKaruppiah Muthumani, Andrew Y Choo, Devon J Shedlock, et al.
Journal of Immunology (Baltimore, Md. : 1950)|August 23, 2011
HIV-mediated phosphatidylinositol 3-kinase/serine-threonine kinase activation in APCs leads to programmed death-1 ligand upregulation and suppression of HIV-specific CD8 T cellsKaruppiah Muthumani, Devon J Shedlock, Daniel K Choo, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 15, 2025
Phase 2 Trial of Long-Acting Cabotegravir and VRC07-523LS for Viral Suppression in Adults with HIV-1: ACTG A5357Babafemi O Taiwo, Yu Zheng, Katherine Rodriguez, et al.
Journal of the International AIDS Society|August 19, 2024
The impact of analytical treatment interruptions and trial interventions on time to viral re-suppression in people living with HIV restarting ART in cure-related clinical studies: a systematic review and meta-analysisMing Jie Lee, Miles Eason, Antonella Castagna, et al.
HIV Research & Clinical Practice|October 14, 2023
Participant experiences in HIV cure-directed trial with an extended analytical treatment interruption in Philadelphia, United StatesAndrea Bilger, Eion Plenn, Frances K Barg, et al.
The Journal of Infectious Diseases|November 17, 2006
Cyclosporin A provides no sustained immunologic benefit to persons with chronic HIV-1 infection starting suppressive antiretroviral therapy: results of a randomized, controlled trial of the AIDS Clinical Trials Group A5138Michael M Lederman, Laura Smeaton, Kim Y Smith, et al.
Pageof 22